Pyxis Raises $50 Million PIPE, Delays Key Data to Fall 2026
Distressed
Company Background
Pyxis Oncology is a Boston-based clinical-stage biopharmaceutical company whose sole meaningful program is micvotabart pelidotin (MICVO), an antibody-drug conjugate that targets extradomain-B of fibronectin (EDB+FN) in the tumor extracellular matrix — a non-cellular target that distinguishes it mechanistically from most approved ADCs. The company's go-forward development focus is recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), a disease with approximately one-year median survival on current standard of care. MICVO holds FDA Fast Track Designation for second-line-and-beyond R/M HNSCC. The company is listed on Nasdaq with a market cap of approximately $166.6 million.
Preliminary Phase 1/2 data released in December 2025 showed a 46% confirmed overall response rate in the monotherapy dose-expansion study (13 efficacy-evaluable patients at 5.4 mg/kg) and a 71% confirmed ORR in the combination study with pembrolizumab (7 evaluable patients). Those headline numbers attracted meaningful attention, though the company simultaneously disclosed that a dose cap was implemented in December 2025 to address tolerability problems in higher-body-weight patients, with all five treatment-related discontinuations occurring in that subgroup.
Leadership has been in a caretaker configuration for months. Dr. Lara Sullivan departed as CEO on February 2, 2026, and board director Tom Civik took over as interim CEO. Civik's employment agreement provides for a $710,000 annualized salary, a 60% target bonus, and two option grants: one representing 1.1% of outstanding shares vesting over 12 monthly installments, and a second representing 0.4% of outstanding shares that vests in full upon the completion of a successful financing or strategic transaction. No permanent CFO has been named since Pamela Connealy's retirement on July 1, 2025; her financial duties were assumed by Jitendra Wadhane, the senior vice president of finance and chief accounting officer.
What Was Disclosed
On June 30, 2026, Pyxis entered into a securities purchase agreement for a private placement, agreeing to sell 19,600,153 shares of common stock at $2.551 per share and common warrants to purchase an equal number of shares at an exercise price of $3.289 per share. The financing is expected to generate gross proceeds of approximately $50 million before placement fees, with an additional approximately $64 million available if the warrants are exercised in full for cash. The deal was led by BVF Partners L.P., with participation from GordonMD Global Investments, RTW Investments, and Coastlands Capital LP. Wells Fargo Securities acted as sole placement agent. The transaction is expected to close July 2, 2026.